Immune Response News and Research

RSS

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3’s scaffolding ability, independent of cell death.

5 Oct 2021

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

A new systematic review and meta-analysis focused on the humoral and cell-mediated immune responses after COVID-19 vaccination in patients undergoing anti-CD20 antibodies treatment.

5 Oct 2021

Managing metabolic disease through time-restricted eating

In this interview, News-Medical speaks to Dr. Satchin Panda about his latest research into time-restricted eating and how it can be used to manage metabolic diseases.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

In the earliest days of the COVID-19 pandemic, the medical community turned to a century-old treatment: Take blood from recovered patients and give it to the sick.

4 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

Researchers launch new study of COVID-19 vaccination schedules in 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Glycerin helps calm the red itchy patches in psoriasis model

Patients with psoriasis have reported that glycerin, an inexpensive, harmless, slightly sweet liquid high on the list of ingredients in many skin lotions, is effective at combatting their psoriasis and now scientists have objective evidence to support their reports.

4 Oct 2021

Using nasopharyngeal microbiota as early biomarker in patients with COVID-19

A new study aimed to analyze the nasopharyngeal microbiota of patients who were hospitalized with COVID-19.

4 Oct 2021

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

A new study addressing this issue has been published in Viruses that shows that functional neutralizing antibody tests are more relevant indicators than the presence or absence of binding antibodies.

4 Oct 2021

Breakthrough research reveals why some Covid patients may die from the disease

The number of Covid cases in the UK has risen 12% this week, but while some people may be hospitalized, others will suffer little more than a loss of smell. London Medical Laboratory says new research is now revealing everyone’s immune system is as unique as their fingerprint.

4 Oct 2021

Study provides insights on kidney transplant recipients’ immune response to SARS-CoV-2 infection

New research provides insights on the immune responses of kidney transplant recipients following infection with the virus that causes COVID-19. The study, which is published in JASN, may help explain why these individuals face a higher risk of dying from COVID-19 than others in the general population.

4 Oct 2021

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the "The New England Journal of Medicine".

3 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

SARS-CoV-2 infection and severity are strongly associated with nasal microbiota

In a recent study, researchers conducted a nasopharyngeal microbiota profiling parallelism in an effort to analyze microbiota variations in COVID-19 patients.

3 Oct 2021

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

A recent study discusses the rate of changes in peripheral blood white cells in individuals who have recovered from SARS-CoV-2 infection.

3 Oct 2021

Northwestern’s SPORE has made advances in understanding the genetic basis of glioblastoma

Glioblastoma is one of the deadliest cancers known to man. While the advent of immunotherapy and other cutting-edge treatments have prolonged life for people afflicted with other types of cancer, the prognosis for glioblastoma has remained relatively constant: just 18 months.

3 Oct 2021

Immune Response News and Research

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

Managing metabolic disease through time-restricted eating

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers launch new study of COVID-19 vaccination schedules in 12-to-16-year-olds

How durable is the immune response generated from the BNT162b2 vaccine?

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

Glycerin helps calm the red itchy patches in psoriasis model

Using nasopharyngeal microbiota as early biomarker in patients with COVID-19

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

Breakthrough research reveals why some Covid patients may die from the disease

Study provides insights on kidney transplant recipients’ immune response to SARS-CoV-2 infection

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

SARS-CoV-2 infection and severity are strongly associated with nasal microbiota

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

Northwestern’s SPORE has made advances in understanding the genetic basis of glioblastoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News